"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative...
Janet Loesberg, PhRMA/Biotech veteran, brings medical and launch expertise.
SUMMIT, N.J., July 28, 2025 /PRNewswire/ -- Vascarta Inc. today announced the addition of Janet Loesberg,...
DELRAY BEACH, Fla., July 28, 2025 /PRNewswire/ -- The global Biosurgery Market, valued at US$14.96 billion in 2024 stood at US$15.83 billion in 2025 and...
DELRAY BEACH, Fla., July 28, 2025 /PRNewswire/ -- The global Biosurgery Market, valued at US$14.96 billion in 2024 stood at US$15.83 billion in 2025 and...
The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...
The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...
DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The global Knee Replacement Surgery Market, valued at US$10.86 billion in 2023 stood at US$12.00 billion in 2025...
Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection
New findings highlight the central role of...
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:
The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...
The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...
Veteran pharma operator co-founded Ategenos to tackle the global $1 trillion crisis of medication non-adherence
CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Ategenos, a pharmatech...
The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....